Puma Biotechnology Inc PBYI:NASDAQ
RT Quote | Last NASDAQ LS, VOL From CTA | USD
After Hours: Last | 4:00 PM EDT6.81UNCH (UNCH)
Volume
8,953
Close
6.81
-0.17 (-2.44%)
-0.17 (-2.44%)Volume
217,206
52 week range
3.03 - 7.90
- Open6.96
- Day High7.04
- Day Low6.79
- Prev Close6.98
- 52 Week High7.90
- 52 Week High Date04/10/26
- 52 Week Low3.03
- 52 Week Low Date08/01/25
Latest On Puma Biotechnology Inc
Key Stats
- Market Cap346.626M
- Shares Out50.90M
- 10 Day Average Volume0.21M
- Dividend-
- Dividend Yield-
- Beta1.21
Latest On Puma Biotechnology Inc
KEY STATS
- Open6.96
- Day High7.04
- Day Low6.79
- Prev Close6.98
- 52 Week High7.90
- 52 Week High Date04/10/26
- 52 Week Low3.03
- 52 Week Low Date08/01/25
- Market Cap346.626M
- Shares Out50.90M
- 10 Day Average Volume0.21M
- Dividend-
- Dividend Yield-
- Beta1.21
RATIOS/PROFITABILITY
- EPS (TTM)0.48
- P/E (TTM)14.28
- Fwd P/E (NTM)18.41
- EBITDA (TTM)40.213M
- ROE (TTM)21.62%
- Revenue (TTM)227.178M
- Gross Margin (TTM)74.46%
- Net Margin (TTM)10.73%
- Debt To Equity (MRQ)8.79%
EVENTS
- Earnings Date08/05/2026(est)
- Ex Div Date-
- Div Amount-
- Split Date-
- Split Factor-
Content From Our Affiliates
Related Video
watch now
Profile
MOREPuma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of products to enhance cancer care. The Company is commercializing NERLYNX, an oral version of neratinib, for the treatment of certain HER2-positive breast cancers. NERLYNX is approved in the United States for two indications: the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant...
Alan Auerbach
Chairman of the Board, President, Chief Executive Officer, Secretary
Maximo Nougues
Chief Financial Officer
Address
10880 Wilshire Blvd., Suite 2150
Los Angeles, CA
90024
United States